DoW Lung Cancer Translational Research Award

The Defense Health Agency’s FY26 Lung Cancer Research Program Translational Research Award provides grant funding for advanced translational lung cancer research aimed at moving promising ideas toward clinical applications. The program supports studies that address at least one FY26 LCRP area of emphasis, with two tracks for advanced or late-stage preclinical and correlative studies or for pilot clinical trials of novel interventions. Review focuses on military health relevance, research strategy, impact, and a transition plan for moving findings into clinical application, and eligible applicants may include U.S. and foreign organizations with an independent investigator serving as principal investigator. The process uses a two-step submission with a pre-application due June 23, 2026, and an invitation required for the full application due September 2, 2026; the opportunity provides about $9.1 million across an expected six awards, with support listed at up to $1.35 million for three years or $1.85 million for four years depending on funding level.